Tiefe Beinvenenthrombosen bei Intensivpatienten mit COVID-19-Infektion – Einfluss eines standardisierten Therapieregimes

Zusammenfassung

Hintergrund und Fragestellung Die erhöhte Inzidenz tiefer Beinvenenthrombosen (TVT) bei Intensivpatienten mit COVID-19-Infektion ist mehrfach beschrieben worden. Kann das Thromboserisiko bei diesen Patienten durch standardisierte Systemtherapie gesenkt werden?

Material und Methoden Nach Etablierung eines Therapiestandards mit Vollantikoagulation, Gabe von Dexamethason und Rekonvaleszentenplasma wurden 20 Patienten mit COVID-19-Pneumonie auf das Vorliegen einer TVT mittels Kompressionssonografie gescreent. Als Vergleichsgruppe dienten 20 COVID-Infizierte mit noch uneinheitlicher Therapie, die wir während der 1. Erkrankungswelle auf das Vorliegen einer Thrombose untersucht haben.

Ergebnisse In der aktuellen Studienpopulation mit standardisiertem Therapieregime konnten wir keine Thrombose detektieren, wohingegen im COVID-Kollektiv unserer Voruntersuchung 20% der Erkrankten (n=4) eine TVT entwickelten. Lungenembolien traten in beiden Gruppen auf; 1 in der 1., 2 in der 2. Kohorte.

Diskussion Durch Vollantikoagulation, Steroidgabe und Verabreichen von Rekonvaleszentenplasma konnte das TVT-Risiko gesenkt werden. Die dezidierte Bedeutung der einzelnen Komponenten ist nicht geklärt. Da Blutungen bei SARS-CoV-2-Infektion bisher nur selten beobachtet wurden, scheint eine großzügige Indikation zur Antikoagulation gerechtfertigt.

Abstract

Background and Objectives It has been reported that the risk of deep vein thrombosis is greater in patients with COVID-19 infection. We have now investigated whether a standardised therapy can reduce the risk of DVT.

Materials and Methods After establishing standard therapy with anticoagulation, steroids and convalescent plasma, we screened 20 patients with COVID-19 pneumonia for DVT by ultrasound examination. The comparison group contained 20 COVID patients with inconsistent therapy, who were examined for the presence of thrombosis during the first wave.

Results In the current patient population with standard therapy, we could not detect any thrombosis, and in the prior patients group only 25% of patients developed DVT. Pulmonary embolism was found in one patient in the first cohort and two in the second.

Conclusion The risk of DVT could be reduced through anticoagulation, and administration of steroids and convalescent plasma. The specific significance of the individual components has not yet been clarified. Since bleeding is a rarely observed in SARS-CoV-2 infections, a generous indication for anticoagulation seems to be justified.

Schlüsselwörter

COVID-19 - Thrombose - Antikoagulation - Rekonvaleszentenplasma - Steroide

Keywords

COVID-19 - Thrombosis - Anticoagulation - convalescent plasma - steroids

Publication History

Received: 03 July 2021

Accepted after revision: 29 August 2021

Article published online:
27 October 2021

• Literatur

• 1 Klok FA, Kruip M, van der Meer NJM. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148-150 DOI: 10.1016/j.thromres.2020.04.041. (PMID: 32381264)
• 2 Zerwes S, Hernandez Cancino F, Liebetrau D. et al. Erhöhtes Risiko für tiefe Beinvenenthrombosen bei Intensivpatienten mit CoViD-19-Infektion? – Erste Daten. Chirurg 2020; 91: 588-594 DOI: 10.1007/s00104-020-01222-7.
• 3 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381s-453s DOI: 10.1378/chest.08-0656. (PMID: 18574271)
• 4 Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost 2015; 41: 68-74 DOI: 10.1055/s-0034-1398386. (PMID: 25594495)
• 5 Klok FA, Kruip M, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147 DOI: 10.1016/j.thromres.2020.04.013. (PMID: 32291094)
• 6 Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020; 46: 1105-1108 DOI: 10.1007/s00134-020-06059-6. (PMID: 32347323)
• 7 Zerwes S, Steinbauer M, Gosslau Y. et al. COVID-19-Infektion – Risiko für thrombembolische Komplikationen. Gefasschirurgie 2020; 25: 397-402 DOI: 10.1007/s00772-020-00687-4.
• 8 Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol 2020; 39: 2529-2543 DOI: 10.1007/s10067-020-05275-1. (PMID: 32654082)
• 9 Cui S, Chen S, Li X. et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1421-1424 DOI: 10.1111/jth.14830. (PMID: 32271988)
• 10 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100 DOI: 10.1378/chest.10-0134. (PMID: 20299623)
• 11 Cattaneo M, Bertinato EM, Birocchi S. et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?. Thromb Haemost 2020; 120: 1230-1232 DOI: 10.1055/s-0040-1712097. (PMID: 32349132)
• 12 Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost 2020; 26: 1076029620938149 DOI: 10.1177/1076029620938149. (PMID: 32677459)
• 13 Hasan SS, Radford S, Kow CS. et al. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis 2020; 50: 814-821 DOI: 10.1007/s11239-020-02235-z. (PMID: 32748122)
• 14 Mager S, Karagiannidis C, Mikolajewska A. et al. COVID-19: Evidenzbasierte Therapieoptionen. Dtsch Arztebl 2020; 117: A-2340/B-1974
• 15 White D, MacDonald S, Bull T. et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020; 50: 287-291 DOI: 10.1007/s11239-020-02145-0. (PMID: 32445064)
• 16 Beun R, Kusadasi N, Sikma M. et al. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42 (Suppl. 01) 19-20 DOI: 10.1111/ijlh.13230. (PMID: 32311843)
• 17 Lopes RD, Fanaroff AC. Anticoagulation in COVID-19: It Is Time for High-Quality Evidence. J Am Coll Cardiol 2020; 76: 1827-1829 DOI: 10.1016/j.jacc.2020.09.008. (PMID: 33059827)
• 18 Malas MB, Naazie IN, Elsayed N. et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine 2020; 29: 100639 DOI: 10.1016/j.eclinm.2020.100639. (PMID: 33251499)
• 19 Magro C, Mulvey JJ, Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220: 1-13 DOI: 10.1016/j.trsl.2020.04.007. (PMID: 32299776)
• 20 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033-2040 DOI: 10.1182/blood.2020006000. (PMID: 32339221)
• 21 Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Spinner CD, Malin JJ, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe KF, Hoffmann F, Böttiger BW, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Haase R, Nothacker M, Marx G, Karagiannidis C, Fichtner F, Laudi S, Stegemann M, Skoetz N. Team des COVID-19 Evidenzökosystem (CEOsys) Projektes. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. Im Internet (Stand: 17.05.2021): https://www.awmf.org/uploads/tx_szleitlinien/113–001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19__2021–05.pdf
• 22 Chatterjee K, Wu CP, Bhardwaj A. et al. Steroids in COVID-19: An overview. Cleve Clin J Med 2020; DOI: 10.3949/ccjm.87a.ccc059. (PMID: 32819962)
• 23 Rizk JG, Kalantar-Zadeh K, Mehra MR. et al. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs 2020; 80: 1267-1292 DOI: 10.1007/s40265-020-01367-z. (PMID: 32696108)
• 24 Perico L, Benigni A, Casiraghi F. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 2021; 17: 46-64 DOI: 10.1038/s41581-020-00357-4. (PMID: 33077917)
• 25 Rojas M, Rodríguez Y, Monsalve DM. et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020; 19: 102554 DOI: 10.1016/j.autrev.2020.102554. (PMID: 32380316)
• 26 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382: e38 DOI: 10.1056/NEJMc2007575. (PMID: 32268022)
• 27 Tan WYT, Young BE, Lye DC. et al. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep 2020; 10: 17458 DOI: 10.1038/s41598-020-74492-0. (PMID: 33060704)
• 28 Smith NL, Harrington LB, Blondon M. et al. The association of statin therapy with the risk of recurrent venous thrombosis. J Thromb Haemost 2016; 14: 1384-1392 DOI: 10.1111/jth.13334. (PMID: 27061794)
• 29 Subir R, Jagat JM, Kalyan KG. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr 2020; 14: 1225-1229 DOI: 10.1016/j.dsx.2020.07.011.
• 30 Dashti-Khavidaki S, Khalili H. Considerations for Statin Therapy in Patients with COVID-19. Pharmacotherapy 2020; 40: 484-486 DOI: 10.1002/phar.2397. (PMID: 32267560)
• 31 Gordon AC, Mouncey PR, Al-Beidh F. et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021; 384: 1491-1502 DOI: 10.1056/NEJMoa2100433. (PMID: 33631065)
• 32 Devreese KMJ, Linskens EA, Benoit D. et al. Antiphospholipid antibodies in patients with COVID-19: A relevant observation?. J Thromb Haemost 2020; 18: 2191-2201 DOI: 10.1111/jth.14994. (PMID: 32619328)
• 33 Hippensteel JA, Burnham EL, Jolley SE. Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol 2020; 190: e134-e137 DOI: 10.1111/bjh.16908. (PMID: 32484907)
• 34 Kapoor S, Chand S, Dieiev V. et al. Thromboembolic Events and Role of Point of Care Ultrasound in Hospitalized Covid-19 Patients Needing Intensive Care Unit Admission. J Intensive Care Med 2020; DOI: 10.1177/0885066620964392.